The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | CARTITUDE-1 final results: cilta-cel in heavily pretreated patients with R/R myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the final results of the CARTITUDE-1 trial (NCT03548207), which is evaluating ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory (R/R) multiple myeloma. Dr Lin summarizes the median progression-free survival (PFS) observed in patients, and further shares her excitement for the Phase III CARTITUDE-4 trial (NCT04181827). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
